Naltrexone hydrochloride is under clinical development by Indivior and currently in Phase II for Alcohol Addiction. According to GlobalData, Phase II drugs for Alcohol Addiction does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Naltrexone hydrochloride LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Naltrexone hydrochloride overview

Naltrexone hydrochloride (OPNT-002) is under development for the treatment of alcohol use disorder (AUD). It is administered through intranasal route, and developed based on nasal spray delivery technology. The drug candidate acts by targeting mu opioid receptor.

Indivior overview

Indivior develops and markets medicines for the treatment of opioid addiction. The company offers suboxone a monthly depot, and only approved film treatment for opioid dependence; subutex, a mono-buprenorphine sublingual tablet, sublocad injection, and nalscue for opioid use disorder; and perseris for schizophrenia. Its pipeline portfolio encompasses buprenorphine-based products, including INDV-1000 in pre-clinical phase and INDV-2000 in Phase I for substance use disorder; and AEF0117 in Phase II for treatment of cannabis disorder. Indivior offers products in the form of film, tablets, and subutex tabs. It provides its products in the US, Australia, Malaysia, France, Italy; Spain, Germany, Canada, and the UK. Indivior is headquartered in Slough, the UK.

For a complete picture of Naltrexone hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.